Age  	Age  	 NN	O
and  	and  	 CC	O
indications  	indications  	 NNS	O
to  	to  	 TO	O
SLIT  	SLIT  	 NNP	O
Clinical  	Clinical  	 NNP	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	I-NP
sublingual  	sublingual  	 JJ	I-NP
immunotherapy  	immunotherapy  	 NNS	I-NP
( 	( 	 -LRB-	O
SLIT 	SLIT 	 NNP	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
investigated  	investigated  	 VBN	O
during  	during  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
20  	20  	 CD	O
years  	years  	 NNS	O
and  	and  	 CC	O
results  	results  	 NNS	O
of  	of  	 IN	O
several  	several  	 JJ	O
meta-analyses  	meta-analyses  	 NNS	B-NP
are  	are  	 VBP	O
available 	available 	 JJ	O
,  	,  	 ,	O
showing  	showing  	 VBG	O
clinical  	clinical  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
in  	in  	 IN	O
children  	children  	 NNS	O
both  	both  	 CC	O
in  	in  	 IN	O
allergic  	allergic  	 JJ	B-NP
asthma  	asthma  	 NN	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
rhinitis 	rhinitis 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
strict  	strict  	 JJ	O
recommendations  	recommendations  	 NNS	B-NP
are  	are  	 VBP	O
not  	not  	 RB	O
possible  	possible  	 JJ	O
under  	under  	 IN	O
current  	current  	 JJ	O
evidence 	evidence 	 NN	O
.  	.  	 .	O
Minimum  	Minimum  	 JJ	B-NP
age  	age  	 NN	I-NP
for  	for  	 IN	I-NP
starting  	starting  	 VBG	I-NP
SLIT  	SLIT  	 NNP	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
clearly  	clearly  	 RB	O
defined  	defined  	 VBN	O
but  	but  	 CC	O
several  	several  	 JJ	O
position  	position  	 NN	B-NP
paper  	paper  	 NN	I-NP
and  	and  	 CC	O
guidelines  	guidelines  	 NNS	O
indicate  	indicate  	 VBP	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
limit  	limit  	 NN	O
of  	of  	 IN	O
5  	5  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age 	age 	 NN	O
.  	.  	 .	O
Guidelines  	Guidelines  	 NNS	O
on  	on  	 IN	O
allergic  	allergic  	 JJ	B-NP
rhinitis  	rhinitis  	 NN	I-NP
suggests  	suggests  	 VBZ	O
SLIT  	SLIT  	 NNP	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
not  	not  	 RB	O
well  	well  	 RB	O
controlled  	controlled  	 VBN	O
with  	with  	 IN	O
drugs  	drugs  	 NNS	O
or  	or  	 CC	O
those  	those  	 DT	O
who  	who  	 WP	O
refuse  	refuse  	 VBP	O
to  	to  	 TO	O
use  	use  	 VB	O
drugs 	drugs 	 NNS	O
.  	.  	 .	O
Additional  	Additional  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
are  	are  	 VBP	O
prevention  	prevention  	 VBN	O
of  	of  	 IN	O
new  	new  	 JJ	O
sensitizations  	sensitizations  	 NNS	B-NP
( 	( 	 -LRB-	O
evidence  	evidence  	 NN	B-NP
IIa 	IIa 	 NN	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
asthma  	asthma  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
allergic  	allergic  	 JJ	B-NP
rhinitis  	rhinitis  	 NNS	I-NP
( 	( 	 -LRB-	O
evidence  	evidence  	 NN	O
I  	I  	 PRP	O
b 	b 	 LS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Studies  	Studies  	 NNS	O
on  	on  	 IN	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
in  	in  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children  	children  	 NNS	I-NP
are  	are  	 VBP	O
discordant 	discordant 	 JJ	O
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
different  	different  	 JJ	O
relevance  	relevance  	 NN	O
of  	of  	 IN	O
allergic  	allergic  	 NN	O
and  	and  	 CC	O
non  	non  	 JJ	B-NP
allergic  	allergic  	 JJ	I-NP
triggers  	triggers  	 NN	I-NP
of  	of  	 IN	I-NP
symptoms  	symptoms  	 NNS	I-NP
could  	could  	 MD	O
explain  	explain  	 VB	O
the  	the  	 DT	O
discordant  	discordant  	 JJ	O
results  	results  	 NNS	O
obtained  	obtained  	 VBN	O
in  	in  	 IN	O
studies  	studies  	 NNS	O
on  	on  	 IN	O
SLIT  	SLIT  	 NNP	O
and  	and  	 CC	O
asthma 	asthma 	 NN	B-NP
,  	,  	 ,	O
particularly  	particularly  	 RB	O
when  	when  	 WRB	O
pooling  	pooling  	 JJ	O
short  	short  	 JJ	O
and  	and  	 CC	O
long  	long  	 JJ	O
term  	term  	 NN	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
Data  	Data  	 NNS	O
on  	on  	 IN	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
are  	are  	 VBP	O
accruing  	accruing  	 VBG	O
for  	for  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis 	dermatitis 	 NN	I-NP
,  	,  	 ,	O
food  	food  	 NN	B-NP
allergy  	allergy  	 NN	I-NP
and  	and  	 CC	O
latex  	latex  	 JJ	B-NP
allergy 	allergy 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
at  	at  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
state  	state  	 NN	O
of  	of  	 IN	O
knowledge 	knowledge 	 NN	O
,  	,  	 ,	O
SLIT  	SLIT  	 NNP	O
remains  	remains  	 VBZ	O
an  	an  	 DT	O
approach  	approach  	 NN	O
reserved  	reserved  	 VBN	O
to  	to  	 TO	O
research 	research 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
no  	no  	 DT	O
recommendations  	recommendations  	 NNS	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
established 	established 	 VBN	O
.  	.  	 .	O
Some  	Some  	 DT	O
studies  	studies  	 NNS	O
demonstrate  	demonstrate  	 VBP	O
that  	that  	 IN	O
SLIT  	SLIT  	 NNP	O
is  	is  	 VBZ	O
safe  	safe  	 JJ	O
in  	in  	 IN	O
children  	children  	 NNS	O
below  	below  	 IN	O
5  	5  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age 	age 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
limit  	limit  	 NN	O
of  	of  	 IN	O
3  	3  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
